27 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2031
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2037 · Medium confidence
Also notable
Ends Feb 2034 · High confidence
Also notable
Ends Feb 2038 · High confidence
Pharmaceutical Compositions and Methods of Using the Same
US 11,040,032
Cited by 9 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Use of Amisulpride as an Anti-Emetic
US 9,084,765
The most cited patent in this portfolio, cited by 17 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Rescue Treatment of Post Operative Nausea and Vomiting
US 11,357,753
Cited by 4 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Combinations of Amisulpride and Another Anti-Emetic for Treating Nausea and Vomiting (US 10,322,106) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jan 21, 2027The maintenance fee for Use of Amisulpride as an Anti-Emetic (US 9,084,765) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Pharmaceutical Compositions and Methods of Using the Same (US 11,738,015) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 3 fees due Mar 1 to 24, 2027 · next Mar 1
- 1 fee due Jul 7, 2027The maintenance fee for Use of Amisulpride as an Anti-Emetic (US 10,525,033) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Pharmaceutical Compositions and Methods of Using the Same (US 11,911,502) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Pharmaceutical Compositions and Methods of Using the Same | 15 in force | to Feb 2037 |
| Use of Amisulpride as an Anti-Emetic | 8 in force | to Feb 2034 |
| Rescue Treatment of Post Operative Nausea and Vomiting | 3 in force | to Feb 2038 |
| Combinations of Amisulpride and Another Anti-Emetic for Treating Nausea and Vomiting | 1 in force | to Apr 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,686,019 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 9,119,836 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 9,545,426 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 9,889,118 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 10,085,970 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 10,525,033 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 12,194,022 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 9,084,765 | Use of Amisulpride as an Anti-Emetic held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 10,322,106 | Combinations of Amisulpride and Another Anti-Emetic for Treating Nausea and Vomiting held by Lxo Ireland Designated Activity Company; Lxo US, Inc. and Lxo US, Inc. In force · High confidence | In force | High confidence | |
| US 9,867,815 | Pharmaceutical Compositions and Methods of Using the Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 3 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.